Relationship of PPARgamma2 polymorphism with obesity ana metabolic syndrome in postmenopausal polish women

Experimental and Clinical Endocrinology and Diabetes

Volumn 117, Issue 10, 2009, Pages 628-632

  Milewicz, A ^b   Tworowska Bardzinska U ^b   Dunajska, K ^a   Jedrzejuk D ^b   Lwow, F ^a  

^a UNIVERSITY SCHOOL OF PHYSICAL EDUCATION   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Metabolic syndrome; Postmenopausal women; PPARy; Pro 12 Ala polymorphism

Indexed keywords

ALANINE; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PROLINE; TRIACYLGLYCEROL;

ADULT; ALLELE; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY COMPOSITION; BODY FAT; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GENE FREQUENCY; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GLUCOSE BLOOD LEVEL; HETEROZYGOTE; HUMAN; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; OBESITY; POLAND; POLYMERASE CHAIN REACTION; POSTMENOPAUSE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPOSITY; ALLELES; ANALYSIS OF VARIANCE; BODY MASS INDEX; CHI-SQUARE DISTRIBUTION; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; POLAND; POLYMORPHISM, GENETIC; POSTMENOPAUSE; PPAR GAMMA; RISK FACTORS; STATISTICS, NONPARAMETRIC; WAIST CIRCUMFERENCE;

EID: 70450247061     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0028-1112154     Document Type: Article

References (32)

1. Altshuler D, Hirschhorn JN, Klanmmark M et al. The common PPARy Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000; 26: 76-80
2. Beamer BA, Yen CJ, Andersen RE et al Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-y2 gene with obesity in two Caucasian populations. Diabetes 1998; 47:1806-1808
3. Deeb SS, Fajas L, Němoto M et al. A Prol2Ala substitution in PPARy2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998; 20: 284-287 (Pubitemid 28507675)
4. Ek J, Urhammer SA, Serensen TI et al. Homozygosity of the Pro12Ala variant of the peroxisome proliferation-activated receptor-gamma2 (PPAR-gamma2): divergent modulating effects on body mass index in obese and lean Caucasian men. Diabetologia 1999; 42: 892-895
5. Franks PW, Luan J, Browne PO et al. Does peroxisome proliferatoractivated receptor gamma genotype (Pro12Ala) modify the association of physical activity and dietary fat with fasting insulin level? Metabolism 2004; 53: 11-16
6. Frederiksen JL, Bradbaek K, Fenger M et al. Comment: studies of the Prol 2Ala polymorphism of the PPAR-gamma gene in the Danish MONICA cohort: homozygosity of the Ala allele confers a decreased risk of the insulin resistance syndrome. J Clin Endocrinol Metab. 2002; 87: 3989-3992
7. Giusti V, Suter M, Verdumo C et al. Molecular determinants of human adipose tissue: differences between visceral and subcutaneous compartments in obese women. J Clin Endocricol Metab 2004; 89: 1379-1384 (Pubitemid 38368440)
8. González Sánchez JL, Serrano Ríos M, Fernández Perez C et al. Effect of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor gamma-2 gene on adiposity, insulin sensitivity and lipid profile in the Spanish population. Eur J Endocrinol. 2002; 147: 495-501 (Pubitemid 35238145)
9. Greenfield JR, Samaras K, Chishalm DJ. Insulin resistance, intra-abdominal fat, cardiovascular risk factors, and androgens in healthy young women with type I diabetes mellitus. J Clin Endocrinol Metab. 2002; 87:1036-1040 (Pubitemid 36121061)
10. Hara K, Okada T, Tobe K et al. The Pro 12Ala polymorphism in PPARy2 may confer resistance to type 2 diabetes. Biochem Biophys Res Commun 2000; 271: 212-216 (Pubitemid 30444879)
11. Heikkinen S, AuwerxJ, Argmann CA. PPARgamma in human and mouse physiology. Biochim Biophys Acta 2007; 1771: 999-1013
12. Katz A, Nambi SS, Mather K et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000; 85: 2402-2410 (Pubitemid 32269192)
13. Knoblauch H, Busjahn A, Müller-Myhsok B et al. Peroxisome proliferator-activated receptor gamma gene locus is related to body mass index and lipid values in healthy nonobese subjects. Arterioscler Thromb Vase Biol 1999; 19: 2940-2944
14. Kalehmainen M, Uusitupa MI, Alhava E et al. Effect of the Pro12Ala polymorphism in the peroxisome proliferator-activated receptor (PPAR) gamma2 gene on the expression of PPARgamma target genes in adipose tissue of massively obese subjects. J Clin Endocrinol Metab 2003; 88: 1717-1722 (Pubitemid 36623394)
15. Lai K, Harnish DC, Evans MJ. Estrogen receptor alpha regulates expression of the orphan receptor small heterodimer partner. J Biol Chem 2003; 278: 36418-36429
16. Luan J, Browne PO, Harding AH et al. Evidence for gene-nutrient interaction at the PPARgamma locus. Diabetes 2001 ; 50: 686-689 (Pubitemid 32195237)
17. Mandni FP, Vaccaro O, Sabatino L et al. Pro12Ala substitution in the peroxisome proliferator-activated receptor-y2 is not associated with type 2 diabetes. Diabetes 1998; 48: 1466-1468
18. Masud S, Ye S. Effect of the peroxisome proliferator activated receptor-gamma gene Pro12Ala variant on body mass index: a meta-analysis. J Med Genet 2003; 40: 773-780 (Pubitemid 37311078)
19. Mattevi VS, Zembrzuski VM, Hutz MH. Effects of a PPARy gene variant on obesity characteristics in Brazil. Braz J Med Biol Res 2007; 40: 927-932
20. Meirhaeghe A, Amouyel P. Impact of genetic variation of PPAy gamma in humans. Mol Genet Metab 2004; 83: 93-102 (Pubitemid 39311284)
21. Meirhaeghe A, Fajas L, Helbecque N et al. Impact of the peroxisome proliferator-activated receptor y2 Prol2Ala polymorphism on adiposity, lipids and non-insulin-dependent diabetes mellitus. Int J Obesity 2000; 24:195-199 (Pubitemid 30107568)
22. Milewicz A, Twarawska U, Demissie M. Menopausal obesity-myth or fact? Climacteric 2001; 4: 273-283
23. Mori H, lkegami H, Kawaguchi Y et al. The Pro12 - >Ala substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. Diabetes 2001 ; 50: 891-894
24. Ringel J, Engeli S, Distler A et al. Pro12Ala missense mutation of the peroxisome proliferator-activated receptor y and diabetes mellitus. Biochem Biophys Res Commun 1999; 254: 450-453 (Pubitemid 29290421)
25. Semple RK, Chatterjee VK, O'Rahilly S. PPAR gamma and human metabolic disease. J Clin Invest 2006; 116: 581-589 (Pubitemid 43326862)
26. Soriguer F, Morcillo S, Cardona F et al. Pro12Ala polymorphism of the PPARy2 gene is associated with type 2 diabetes mellitus and peripheral insulin sensitivity in a population with a high intake of oleic acid. J Nutr 2006; 136: 2325-2330 (Pubitemid 44329990)
27. Tonjes A, Scholz M, Loeffler M et al. Association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma with prediabetic phenotypes: meta-analysis of 57 studies on nondiabetic individuals. Diabetes Care 2006; 29: 2489-2497 (Pubitemid 44912258)
28. Valve R, Sivenius K, Miettinen R et al. Two polymorphisms in the peroxisome proliferator-activated receptor y gene are associated with severe overweight among obese women. J Clin Endocrinol Metab 1999; 84: 3708-3712 (Pubitemid 30645229)
29. Vidal-Puig A, Considine R, Jimenez-Linan M et al. Peroxisome proliferator-activated receptor gene expression in human tissues: effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest 1997; 99: 2416-2422 (Pubitemid 27227719)
30. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. End Rev 2000; 21: 637-738
31. Yen CJ, Beamer BA, Negri C et al. Molecular scanning of the human peroxisome proliferator activated receptor gamma gene in diabetic Caucasians: identification of a Pro12Ala PPARy2 missense mutation. Biochem Biophys Res Commun 1997; 241: 270-274 (Pubitemid 28020091)
32. Zimmet P, Alberti G, Shaw J. A new IDF worldwide definition of the metabolic syndrome: the rationale and the results. Diabetes Voice 2005; 50: 31-33